Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report

The clinical benefits of HER2 inhibitors in patients with non-small cell lung cancer (NSCLC) have been limited. There is a paucity of effective therapies in NSCLC after developing resistance to initial anti-HER2 therapy. Herein, we presented the clinical benefit of pyrotinib in a 53-year-old patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Jianzhen, Ruan, Jian, Tan, Yanbin, Yan, Li, Chen, Songan, Du, Miaoyan, Wang, Lingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537839/
https://www.ncbi.nlm.nih.gov/pubmed/33061462
http://dx.doi.org/10.2147/OTT.S271999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537839/
https://www.ncbi.nlm.nih.gov/pubmed/33061462
http://dx.doi.org/10.2147/OTT.S271999

Ejemplares similares